SOMERSET, N.J. - September 24, 2020 - Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that it has acquired a new manufacturing facility in Bloomington, Indiana, to create a North American center of excellence for early-phase clinical biologics formulation development and drug product fill/finish services. The $14 million investment includes the acquisition, build-out, and qualification of the facility to begin supporting customer programs starting January 2021. The 23,000-square-foot facility, purchased from AB BioTechnologies, Inc....
|